GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Can Fite Biofarma Ltd (XTAE:CANF) » Definitions » Interest Paid

Can Fite Biofarma (XTAE:CANF) Interest Paid


View and export this data going back to 2005. Start your Free Trial

What is Can Fite Biofarma Interest Paid?

Interest Paid only applicable to companies reporting Cash Flow from Operations in direct method.


Can Fite Biofarma Business Description

Traded in Other Exchanges
Address
26 Ben Gurion Street, Ramat Gan, ISR, 5257346
Can Fite Biofarma Ltd is an clinical-stage biopharmaceutical company. The company develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. The company's platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. The company's drug candidate, Piclidenoson, is currently in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is headed into a Phase III trial for hepatocellular carcinoma (HCC), the common form of liver cancer, and a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH).